MARKET

NAVB

NAVB

Navidea Biopharm
AMEX

Real-time Quotes | Nasdaq Last Sale

0.7799
-0.0701
-8.25%
Opening 12:43 05/27 EDT
OPEN
0.8500
PREV CLOSE
0.8500
HIGH
0.9000
LOW
0.7700
VOLUME
29.46K
TURNOVER
9.15K
52 WEEK HIGH
2.190
52 WEEK LOW
0.7200
MARKET CAP
23.68M
P/E (TTM)
-1.9860
1D
5D
1M
3M
1Y
5Y
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting
DUBLIN, Ohio, May 24, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced acceptance of its abstract ti...
Business Wire · 4d ago
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting
DUBLIN, Ohio, May 23, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced acceptance of its abstract ti...
Business Wire · 5d ago
Navidea Biopharm GAAP EPS of -$0.10
Navidea Biopharm press release (NYSE:NAVB): Q1 GAAP EPS of -$0.10. $1.2 million in cash and cash equivalents.
Seekingalpha · 05/12 12:16
BRIEF-Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results
reuters.com · 05/12 11:32
Navidea's Imaging Agent Can Distinguish Between Fibroid & Non-Fibroid Pathotype Of Rheumatoid Arthritis
Benzinga · 04/20 16:31
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 04/20 13:37
Navidea reports initial data from phase 2b study of imaging agent in rheumatoid arthritis patients
Navidea Biopharmaceuticals (NYSE:NAVB) reported preliminary results from an ongoing phase 2b study of imaging agent Tc99m Tilmanocept. The main goal of the trial, dubbed NAV3-32, is to assess the relationship between joint-specific tilmanocept uptake
Seekingalpha · 04/20 12:39
Navidea Biopharmaceuticals Announces Preliminary Results Of Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis
Data support hypothesis that Tc99m tilmanocept imaging can differentiate fibroid pathotype of rheumatoid arthritis from non-fibroid pathotypes Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the
Benzinga · 04/20 11:07
More
No Data
Learn about the latest financial forecast of NAVB. Analyze the recent business situations of Navidea Biopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NAVB stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
High5.00
Average5.00
Low5.00
Current 0.7701
EPS
Actual
Estimate
-0.10-0.09-0.07-0.05
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 32
Institutional Holdings: 742.82K
% Owned: 2.45%
Shares Outstanding: 30.36M
TypeInstitutionsShares
Increased
7
158.08K
New
5
36.74K
Decreased
8
25.91K
Sold Out
24
84.02K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Director
Alexander Cappello
Vice Chairman/Director
John Scott
Other
Michael Rosol
Independent Director
Amit Bhalla
Independent Director
Malcolm Witter
No Data
No Data
About NAVB
Navidea Biopharmaceuticals, Inc. (Navidea) is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company focuses on two drug product diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694, and therapeutic development programs, including therapeutic applications of Manocept platform. It also focuses on developing multiple precision-targeted products based on Manocept platform by identifying the sites and pathways of undetected disease and provide diagnostic services. Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the product developed and commercialized by Navidea based on the platform.

Webull offers kinds of Navidea Biopharmaceuticals Inc stock information, including AMEX:NAVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAVB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NAVB stock methods without spending real money on the virtual paper trading platform.